Diffusion and perfusion MRI prediction of progression-free survival in patients with hepatocellular carcinoma treated with concurrent chemoradiotherapy

Kyung Ah Kim, Mi Suk Park, Hyun Jun Ji, Jun Yong Park, Kwang Hyub Han, Myeong Jin Kim, Ki Whang Kim

Research output: Contribution to journalArticle

14 Citations (Scopus)

Abstract

Purpose To assess whether MR perfusion and diffusion parameters taken before concurrent chemoradiotherapy (CCRT) are useful imaging biomarkers for predicting progression-free survival (PFS) in patients with hepatocellular carcinoma (HCC). Materials and Methods Twenty patients with locally advanced HCC who had no treatment before CCRT underwent dynamic contrast-enhanced (DCE) and diffusion-weighted MRI. Mean values of the volume transfer constant (K trans), reflex constant (Kep), extravascular extracellular volume fraction (Ve) and the apparent diffusion coefficient (ADC) were estimated on a region of interest. The best cutoff value for each factor was assessed to differentiate between patients who had PFS shorter or longer than the median PFS. Patients were dichotomized in terms of the cutoff value. The survival outcome of the two groups and the predictive ability of each factor on PFS were evaluated. Results Median time to PFS was 179 days. The best cutoff values for ADC, Ktrans, Kep, and Ve was 1.008 × 10-3 mm2 s-1, 0.108 min-1, 0.570 min-1, and 0.298%. Patients with higher ADC had significantly longer PFS than those with lower ADC(P < 0.0001). Conclusion The ADC of HCC acquired before CCRT correlated with PFS and was valuable in the prediction of the clinical outcome of HCC treated with CCRT.

Original languageEnglish
Pages (from-to)286-292
Number of pages7
JournalJournal of Magnetic Resonance Imaging
Volume39
Issue number2
DOIs
Publication statusPublished - 2014 Feb

All Science Journal Classification (ASJC) codes

  • Radiology Nuclear Medicine and imaging

Fingerprint Dive into the research topics of 'Diffusion and perfusion MRI prediction of progression-free survival in patients with hepatocellular carcinoma treated with concurrent chemoradiotherapy'. Together they form a unique fingerprint.

  • Cite this